1. Home
  2. GO vs DRUG Comparison

GO vs DRUG Comparison

Compare GO & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Grocery Outlet Holding Corp.

GO

Grocery Outlet Holding Corp.

N/A

Current Price

$10.18

Market Cap

960.8M

ML Signal

N/A

Logo Bright Minds Biosciences Inc.

DRUG

Bright Minds Biosciences Inc.

N/A

Current Price

$88.91

Market Cap

856.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GO
DRUG
Founded
1946
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Food Chains
Pharmaceuticals and Biotechnology
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
960.8M
856.4M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
GO
DRUG
Price
$10.18
$88.91
Analyst Decision
Hold
Strong Buy
Analyst Count
11
5
Target Price
$14.41
$114.00
AVG Volume (30 Days)
2.0M
89.9K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$4,371,501,000.00
N/A
Revenue This Year
$10.67
N/A
Revenue Next Year
$5.13
N/A
P/E Ratio
N/A
N/A
Revenue Growth
10.13
N/A
52 Week Low
$8.96
$23.18
52 Week High
$19.41
$123.75

Technical Indicators

Market Signals
Indicator
GO
DRUG
Relative Strength Index (RSI) 54.16 59.81
Support Level $10.21 $72.06
Resistance Level $10.42 $97.75
Average True Range (ATR) 0.42 5.26
MACD 0.03 1.36
Stochastic Oscillator 64.45 90.28

Price Performance

Historical Comparison
GO
DRUG

About GO Grocery Outlet Holding Corp.

Grocery Outlet Holding Corp is a grocery store operator in the United States. It is a retailer of quality, name-brand consumables and fresh products sold through a network of independently operated stores. The stores are run by Entrepreneurial independent operators which create a neighborhood feel through personalized customer service and a localized product offering.

About DRUG Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Share on Social Networks: